Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.

MLA

Totani, Haruhito, et al. “Phase I Study of Once Weekly Treatment with Bortezomib in Combination with Lenalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma.” International Journal of Hematology, vol. 103, no. 3, Mar. 2016, pp. 316–21. EBSCOhost, https://doi.org/10.1007/s12185-015-1925-7.

APA

Totani, H., Ri, M., Kato, C., Nakashima, T., Suzuki, N., Hagiwara, S., Kanamori, T., Murakami, S., Masuda, A., Kinoshita, S., Yoshida, T., Narita, T., Ito, A., Kusumoto, S., Ishida, T., Komatsu, H., & Iida, S. (2016). Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma. International Journal of Hematology, 103(3), 316–321. https://doi.org/10.1007/s12185-015-1925-7

Chicago

Totani, Haruhito, Masaki Ri, Chie Kato, Takahiro Nakashima, Nana Suzuki, Shinya Hagiwara, Takashi Kanamori, et al. 2016. “Phase I Study of Once Weekly Treatment with Bortezomib in Combination with Lenalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma.” International Journal of Hematology 103 (3): 316–21. doi:10.1007/s12185-015-1925-7.